Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans

M Hellerstein1, M B Hanley, D Cesar

  • 1Department of Medicine, San Francisco General Hospital, University of California at San Francisco, 94110, USA.

Nature Medicine
|January 12, 1999
PubMed

Insights

HIV-1 infection shortens T-cell survival and impairs production, leading to depletion. Antiretroviral therapy boosts T-cell production, not survival, to restore levels.

Area of Science:

  • Immunology
  • Virology
  • Kinetics

Background:

  • T-cell depletion in late-stage HIV-1 disease is a key concern.
  • The precise mechanisms driving T-cell loss remain debated.

Purpose of the Study:

  • To directly measure circulating T-cell kinetics in healthy and HIV-1-infected individuals.
  • To elucidate the dynamic basis of T-cell depletion and recovery.

Main Methods:

  • Employed a novel, non-radioactive, endogenous labeling technique.
  • Quantified T-cell half-lives and production rates in vivo.

Main Results:

  • Healthy individuals: CD4+ T-cell half-life 87 days, CD8+ T-cell half-life 77 days.
  • HIV-1 infected individuals: Significantly reduced T-cell half-lives, uncompensated by increased production.
  • Antiretroviral therapy: Increased T-cell production rates, not half-lives, leading to elevated CD4+ counts.

Conclusions:

  • HIV-1-induced CD4+ T-cell lymphopenia results from shortened survival and insufficient production.
  • T-cell production systems are critical in HIV-1 pathogenesis and therapy response.

Related Concept Videos